Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC) Meeting Abstract
| Authors: | Pal, S. K.; McDermott, D. F.; Atkins, M. B.; Escudier, B.; Rini, B. I.; Motzer, R. J.; Fong, L.; Joseph, R. W.; Oudard, S.; Ravaud, A.; Bracarda, S.; Rodriguez, C. S.; Lam, E. T.; Choueiri, T. K.; Ding, B.; Quach, C.; Hashimoto, K.; Schiff, C.; Piault, E.; Powles, T. |
| Abstract Title: | Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC) |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Start Page: | 267s |
| Language: | English |
| ACCESSION: | WOS:000487345805341 |
| DOI: | 10.1200/JCO.2019.37.15_suppl.4515 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4515 -- Source: Wos |
